The master regulator FUBP1: its emerging role in normal cell function and malignant development

L Debaize, MB Troadec - Cellular and Molecular Life Sciences, 2019 - Springer
Abstract The human Far Upstream Element (FUSE) Binding Protein 1 (FUBP1) is a
multifunctional DNA-and RNA-binding protein involved in diverse cellular processes. FUBP1 …

Treatment of Richter's transformation with novel therapies

A Bajwa, A Habib, AS Kittai - Current Hematologic Malignancy Reports, 2024 - Springer
Abstract Purpose of Review This review presents recently published clinical trial data and
ongoing investigations regarding the treatment of Richter's transformation (RT). Recent …

Advances in molecular biology and targeted therapy of mantle cell lymphoma

P Klener - International journal of molecular sciences, 2019 - mdpi.com
Mantle cell lymphoma (MCL) is a heterogeneous malignancy with a broad spectrum of
clinical behavior from indolent to highly aggressive cases. Despite the fact that MCL remains …

Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation

L Debaize, H Jakobczyk, S Avner… - Nucleic acids …, 2018 - academic.oup.com
Runt-related transcription factor 1 (RUNX1) is a well-known master regulator of
hematopoietic lineages but its mechanisms of action are still not fully understood. Here, we …

[HTML][HTML] FUBP1 in human cancer: Characteristics, functions, and potential applications

F Zhang, Q Xiong, M Wang, X Cao, C Zhou - Translational Oncology, 2024 - Elsevier
Far upstream element-binding protein 1 (FUBP1) is a single-stranded nucleic acid-binding
protein that binds to the Far Upstream Element (FUSE) sequence and is involved in …

High-risk mantle cell lymphoma in the era of novel agents

E Nabrinsky, AV Danilov, PB Koller - Current hematologic malignancy …, 2021 - Springer
Abstract Purpose of Review Mantle cell lymphoma (MCL) is a heterogenous disease with a
variety of morphologic and genetic features, some of which are associated with high risk …

[HTML][HTML] In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program

K Isaev, T Liu, M Bakhtiari, K Tong, R Goswami… - …, 2023 - ncbi.nlm.nih.gov
Intratumoral heterogeneity (ITH) provides the substrate for tumor evolution and treatment
resistance, yet is remarkably understudied in lymphoma, due to the often limited amount of …

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Secondary Acquisition of t (11; 14)(q13; q32)/CCND1-IGH: A Rare Variant Of Richter …

Y Zhao, J McCracken, C Rehder, E Wang - Clinical Lymphoma Myeloma …, 2022 - Elsevier
Introduction Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
occasionally undergoes Richter transformation, mostly to diffuse large B-cell lymphoma, but …

Blastoid Variant Mantle Cell Lymphoma Expressing Aberrant CD3 and CD10 with Concurrent Small Lymphocytic Lymphoma: Establishment of a Clonal Relationship …

CL Felten, JA Chan, DR DeCastro… - Case Reports in …, 2018 - Wiley Online Library
Mantle cell lymphoma (MCL) is an aggressive non‐Hodgkin B‐cell lymphoma typically
expressing CD19, CD20, CD5, FMC‐7, CyclinD1, and SOX‐11 and harboring the …

Lymphoid Pathology on Small Biopsies (FNA and Small Core)–Advantages and Limitations: Guidelines for Ancillary Studies According to Clinical Scenario and …

KM Hogan, AS Lagoo, KV Inamdar - Practical Lymph Node and Bone …, 2020 - Springer
As therapeutic options for various lymphomas have rapidly expanded in the last decade,
accurate classification and prognostic stratification of common and uncommon lymphoma …